Xencor reported $-77.86M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Arrowhead Research USD -141.26M 182.07M Mar/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
Bristol-Myers Squibb USD 299M 3.26B Jun/2026
Cytokinetics USD -181.23M 2.86M Mar/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
J&J USD 7.48B 860M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -31.88M 19.79M Mar/2026
Merck USD 840M 2.72B Jun/2026
Novartis USD 4.73B 549M Jun/2026
Pfizer USD -180M 5.16B Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Xencor USD -77.86M 24.23M Mar/2026